Pharmacology of ergot alkaloids in clinical use.
D000818:Animals; D001927:Brain Diseases / Q000188:drug therapy; D001971:Bromocriptine / Q000494:pharmacology; D004087:Dihydroergotamine / Q000494:pharmacology; D004088:Dihydroergotoxine / Q000031:analogs & derivatives / Q000494:pharmacology; D018492:Dopamine Antagonists; D004876:Ergot Alkaloids / Q000494:pharmacology* / Q000627:therapeutic use; D004878:Ergotamine / Q000494:pharmacology; D005260:Female; D006801:Humans; D008784:Methysergide / Q000494:pharmacology / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D010902:Pituitary Gland / Q000187:drug effects; D011388:Prolactin / Q000378:metabolism; D011941:Receptors, Adrenergic / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects; D014599:Uterus / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects
D018492:Dopamine Antagonists; D004876:Ergot Alkaloids; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D004088:Dihydroergotoxine; D001971:Bromocriptine; D004087:Dihydroergotamine; D011388:Prolactin; D004878:Ergotamine; D008784:Methysergide